Clinical Trial Update: Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating LEO 90100 Aerosol Foam and Daivobet Gel in psoriasis vulgaris has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Daivobet Gel (calcipotriene and betamethasone dipropionate)
• LEO 90100 Aerosol Foam

Snippet

Sponsor: LEO Pharma | Conditions: Psoriasis Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2016-12-28